证券代码：300676 证券简称：华大基因 公告编号：2024-062 深圳华大基因股份有限公司 关于增加 2024 年度日常关联交易预计额度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、日常关联交易基本情况 （一）2024 年度日常关联交易概述 年日常关联交易预计额度事项在提交董事会审议前已经第四届董事会独立董事 专门会议第一次会议审议通过。 3、按照《深圳证券交易所创业板股票上市规则》等相关法规及《公司章程》 《关联交易管理制度》的相关规定，公司本次增加 2024 年度日常关联交易预计 额度事项在公司董事会审批权限范围内，无需提交公司股东大会审议。 2 1、深圳华大基因股份有限公司（以下简称华大基因或公司）于 2024年 1月 19 日召开的第三届董事会第二十三次会议和 2024 年 2 月 5 日召开的 2024 年第 一次临时股东大会，审议通过了《关于 2024 年度日常关联交易预计的议案》。 根据公司业务发展及日常经营的需要，同意公司 2024 年度在人民币 129,921 万 元（以下万元均指人民币万元）的日常关联交易额度内，向关联方 ...

证券代码：300676 证券简称：华大基因 公告编号：2024-063 深圳华大基因股份有限公司 关于 2024 年半年度计提信用减值损失、资产减值损失和核销资 产的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次计提信用减值损失、资产减值损失和核销资产的概述 为客观、公允反映公司截至 2024 年 6 月 30 日的财务状况、资产价值及经营 成果，基于谨慎性原则，公司对合并报表范围内截至 2024 年 6 月 30 日的应收账 款、其他应收款、存货、固定资产、其他非流动资产、商誉等各类资产进行了全 面清查，对各项资产减值的可能性进行了充分的评估和分析，对存在减值迹象的 资产计提相应减值准备。 （一）计提信用减值损失及资产减值损失的资产范围和金额 公司 2024 年 1-6 月计提信用减值和资产减值的资产项目主要是应收账款、其 他应收款、存货，其中，计提信用减值损失人民币 58,184,315.11 元（以下均指人 民币元）；计提资产减值损失 2,501,207.12 元。 单位：人民币元 类别 项目 2024 年 1-6 月发 生额 一、信用减 ...

[Important Notice, Table of Contents, and Definitions](index=2&type=section&id=Item%201.%20Important%20Notice%2C%20Table%20of%20Contents%2C%20and%20Definitions) This chapter provides standard statements, the table of contents, and definitions of key terms and company entities, ensuring the report's truthfulness, accuracy, and completeness - This chapter includes standard statements, the table of contents, and definitions of key terms and company entities, providing foundational information for understanding the report, with the Board, Supervisory Board, and senior management ensuring its truthfulness, accuracy, and completeness[2](index=2&type=chunk)[3](index=3&type=chunk)[5](index=5&type=chunk) [Company Profile and Key Financial Indicators](index=10&type=section&id=Item%202.%20Company%20Profile%20and%20Key%20Financial%20Indicators) This section provides the company's basic information and presents key financial performance indicators for the reporting period [Company Profile](index=10&type=section&id=I.%20Company%20Profile) This chapter provides the company's basic information, including its stock ticker "BGI Genomics", stock code "300676", listing exchange, full Chinese and English names, and legal representative Company Basic Information | Item | Content | | :--- | :--- | | Stock Abbreviation | BGI Genomics | | Stock Code | 300676 | | Stock Exchange | Shenzhen Stock Exchange | | Company's Chinese Name | 深圳华大基因股份有限公司 | | Company's English Name | BGI Genomics Co.,Ltd. | | Legal Representative | Zhao Lijian | [Key Accounting Data and Financial Indicators](index=11&type=section&id=IV.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) During the reporting period, the company experienced significant declines in both operating revenue and net profit, with operating revenue decreasing by 9.67% and net profit attributable to shareholders plummeting by 63.45% Key Financial Indicators for H1 2024 | Indicator | Current Reporting Period | Prior Period (Adjusted) | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue (RMB) | 1,871,450,587.02 | 2,071,830,715.34 | -9.67% | | Net Profit Attributable to Shareholders (RMB) | 18,199,776.02 | 49,788,771.48 | -63.45% | | Net Profit Attributable to Shareholders Excluding Non-Recurring Items (RMB) | 1,214,292.53 | 56,034,837.54 | -97.83% | | Net Cash Flow from Operating Activities (RMB) | -80,476,821.12 | 2,325,389.52 | -3,560.79% | | Basic Earnings Per Share (RMB/share) | 0.0433 | 0.1215 | -64.36% | | Weighted Average Return on Net Assets | 0.18% | 0.50% | -0.32% | [Non-Recurring Gains and Losses and Amounts](index=12&type=section&id=VI.%20Non-Recurring%20Gains%20and%20Losses%20and%20Amounts) During the reporting period, the company's total non-recurring gains and losses amounted to **16.99 million RMB**, primarily from government subsidies and investment income Details of Non-Recurring Gains and Losses | Item | Amount (RMB) | | :--- | :--- | | Government subsidies recognized in current profit or loss | 17,509,712.36 | | Gains or losses from entrusted investments or asset management | 12,789,420.48 | | Gains or losses from changes in fair value of financial assets and liabilities | -9,288,706.63 | | Gains or losses from disposal of non-current assets | -1,079,387.04 | | Other non-operating income and expenses | 646,145.22 | | **Total** | **16,985,483.49** | [Management Discussion and Analysis](index=13&type=section&id=Item%203.%20Management%20Discussion%20and%20Analysis) This section provides an in-depth analysis of the company's main business, operational performance, core competencies, and key risks during the reporting period [Company's Main Business Activities During the Reporting Period](index=13&type=section&id=I.%20Company%27s%20Main%20Business%20Activities%20During%20the%20Reporting%20Period) The company's core business involves providing research services and precision medicine testing solutions to medical and research institutions using multi-omics technologies - The company's business comprehensively covers the entire gene industry value chain and application fields, including reproductive health, oncology prevention, and infection control, committed to safeguarding human health through technological innovation[21](index=21&type=chunk) - During the reporting period, the company launched Geline Lingxi, an AI+ one-stop NGS laboratory solution, aiming to lower the entry barrier for NGS testing and promote precision medicine in grassroots medical institutions through integrated automation and intelligent technologies[27](index=27&type=chunk) [Main Businesses, Products, and Uses](index=13&type=section&id=(I)%20Main%20Businesses%2C%20Products%2C%20and%20Uses) This section details the company's core business segments, including reproductive health, oncology, infection control, multi-omics, and precision medicine, outlining their respective products and applications [Main Business Model](index=16&type=section&id=(II)%20Main%20Business%20Model) This section describes the company's operational strategies, encompassing its service delivery, sales channels, and collaboration models within the genetic testing and precision medicine industry [Key Performance Drivers](index=17&type=section&id=(III)%20Key%20Performance%20Drivers) This section identifies the primary factors influencing the company's financial performance, such as technological innovation, market expansion, policy support, and public health demands [Industry Landscape and Company's Industry Position](index=20&type=section&id=(IV)%20Industry%20Landscape%20and%20Company%27s%20Industry%20Position) This section analyzes the competitive environment and the company's standing within the genetic testing and precision medicine industry, highlighting its market share and strategic advantages [Overview of Operations During the Reporting Period](index=24&type=section&id=(V)%20Overview%20of%20Operations%20During%20the%20Reporting%20Period) In H1 2024, operating revenue decreased by 9.67% to **1.87 billion RMB**, and net profit attributable to shareholders fell by 63.45% to **18.20 million RMB**, primarily due to reduced infection control and precision medicine revenue Overall Operating Performance for H1 2024 | Indicator | Amount (Million RMB) | YoY Change | | :--- | :--- | :--- | | Operating Revenue | 1,871.45 | -9.67% | | Net Profit Attributable to Shareholders | 18.20 | -63.45% | [Reproductive Health Business](index=24&type=section&id=(1)%20Deepening%20Reproductive%20Health%20Business%2C%20Expanding%20Birth%20Defect%20Prevention%20and%20Control%20Advantages) Reproductive health business achieved **607 million RMB** in operating revenue, growing by 7.19%, with strong growth in carrier screening and genetic testing sub-segments Reproductive Health Business Revenue and Growth | Business Segment | H1 2024 Operating Revenue (Million RMB) | YoY Growth | | :--- | :--- | :--- | | **Reproductive Health Business** | **607** | **7.19%** | | Carrier Screening | - | Approx. 41.19% | | Chromosomal Abnormality Detection (CNV-seq) | - | Approx. 28.65% | | Newborn Genetic Disease Screening | - | Approx. 32.18% | | Genetic Disease Testing Series | - | Approx. 38.62% | - As of the end of the reporting period, the company's reproductive health testing products have cumulatively served over **31 million person-times**, with non-invasive prenatal genetic testing exceeding **16.79 million person-times**, solidifying its market leadership[59](index=59&type=chunk) [Oncology and Chronic Disease Prevention and Control Business](index=25&type=section&id=(2)%20Focusing%20on%20Oncology%20and%20Chronic%20Disease%20Prevention%20and%20Control%20Business%2C%20Optimizing%20Main%20Product%20Layout) Oncology and chronic disease prevention business generated **248 million RMB** in revenue, a 13.69% increase, driven by significant growth in colorectal cancer and hereditary tumor genetic testing Oncology and Chronic Disease Prevention and Control Business Revenue and Growth | Business Segment | H1 2024 Operating Revenue (Million RMB) | YoY Growth | | :--- | :--- | :--- | | **Oncology and Chronic Disease Prevention and Control Business** | **248** | **13.69%** | | Colorectal Cancer Testing | - | Approx. 189.12% | | Hereditary Tumor Genetic Testing | - | Approx. 33.65% | - As of the end of the reporting period, over **1.30 million** fecal DNA methylation tests and **7.50 million** HPV genotyping services have been completed globally, demonstrating the initial success of large-scale public health projects[63](index=63&type=chunk) [Infection Prevention and Control Business](index=26&type=section&id=(3)%20Deepening%20Layout%20in%20Difficult%20and%20Critical%20Infection%20Business%2C%20Promoting%20Leapfrog%20Development%20of%20Infection%20Prevention%20and%20Control%20Business) Infection prevention and control business revenue significantly declined by 73.25% to **38 million RMB**, primarily due to reduced public health event-related income and stricter regulations on external sample testing Infection Prevention and Control Business Revenue | Business Segment | H1 2024 Operating Revenue (Million RMB) | YoY Growth | | :--- | :--- | :--- | | **Infection Prevention and Control Business** | **38** | **-73.25%** | - The performance decline is mainly attributed to a significant year-on-year decrease in operating revenue from public health events and stricter domestic regulations on medical institution sample outsourcing[68](index=68&type=chunk) [Multi-Omics Big Data and Synthesis Business](index=27&type=section&id=(4)%20Vigorously%20Developing%20Multi-Omics%20Big%20Data%20and%20Synthesis%20Business%2C%20Expanding%20New%20Product%20Space) Multi-omics and synthesis business revenue decreased by 7.49% to **304 million RMB**, mainly due to geopolitical impacts on tech services in Europe and America, despite strong metagenomic sequencing growth Multi-Omics and Synthesis Business Revenue | Business Segment | H1 2024 Operating Revenue (Million RMB) | YoY Growth | | :--- | :--- | :--- | | **Multi-Omics and Synthesis Business** | **304** | **-7.49%** | | Metagenomic Sequencing Business | - | Approx. 13.23% | [Precision Medicine Testing Integrated Solutions Business](index=29&type=section&id=(5)%20Actively%20Expanding%20Precision%20Medicine%20Business%2C%20Seizing%20Development%20High%20Ground) Precision medicine solutions revenue decreased by 17.00% to **664 million RMB** due to reduced public health event-related income, though regular business grew by 33.19% Precision Medicine Testing Integrated Solutions Business Revenue | Business Segment | H1 2024 Operating Revenue (Million RMB) | YoY Growth | | :--- | :--- | :--- | | **Precision Medicine Testing Integrated Solutions** | **664** | **-17.00%** | - Excluding the impact of public health events, this business segment's operating revenue increased by **33.19%** year-on-year[76](index=76&type=chunk) - Overseas business expansion made progress, with operating revenue in the Southeast Asia region growing by over **70%** year-on-year[76](index=76&type=chunk) [Analysis of Core Competencies](index=48&type=section&id=II.%20Analysis%20of%20Core%20Competencies) The company's core competencies include comprehensive qualifications, a global laboratory network, robust R&D, extensive product lines, global strategy, and AI integration for precision medicine - The company possesses comprehensive qualification advantages, including 20 medical institution practice licenses, **251** domestic medical device registration certificates/filings, and **369** overseas medical device qualifications, covering 25 countries and regions such as the EU and Japan[108](index=108&type=chunk) - The company operates one of the world's largest medical gene testing centers, with 28 gene testing laboratories and approximately 900 joint laboratories established with thousands of global medical institutions, forming a significant scale and layout advantage[110](index=110&type=chunk) - The company highly values R&D innovation, holding **711** authorized patents (including **605** invention patents) and **852** software copyrights as of the reporting period, ensuring sustainable development through its extensive product line[114](index=114&type=chunk)[115](index=115&type=chunk) - The company strategically invests in AI, developing Genetic Transformer (GeneT), an AI large language model-driven method for identifying pathogenic variants in rare genetic diseases, enhancing analysis efficiency and clinical application value[126](index=126&type=chunk) [Analysis of Main Business](index=54&type=section&id=III.%20Analysis%20of%20Main%20Business) This chapter presents year-on-year financial data changes for main businesses, showing a 9.67% revenue decrease, 11.84% cost decrease, and a significant 39.05% drop in financial expenses Key Financial Data Year-on-Year Changes | Item | Current Reporting Period (RMB) | Prior Period (RMB) | YoY Change | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 1,871,450,587.02 | 2,071,830,715.34 | -9.67% | - | | Operating Cost | 987,547,295.68 | 1,120,165,357.30 | -11.84% | - | | Selling Expenses | 398,275,857.99 | 463,819,429.61 | -14.13% | - | | Financial Expenses | -26,960,620.66 | -19,389,304.84 | -39.05% | Primarily due to increased bank deposit interest income | | Net Cash Flow from Operating Activities | -80,476,821.12 | 2,325,389.52 | -3,560.79% | Primarily due to decreased cash received from sales of goods and services | Operating Performance by Product or Service | Product or Service Segment | Operating Revenue (RMB) | Operating Cost (RMB) | Gross Margin | YoY Change in Operating Revenue | YoY Change in Operating Cost | YoY Change in Gross Margin | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Reproductive Health Basic Research and Clinical Application Services | 606,960,394.09 | 329,537,024.49 | 45.71% | 7.19% | 2.10% | 2.71% | | Oncology and Chronic Disease Prevention & Control and Translational Medicine Services | 247,672,248.61 | 155,844,804.28 | 37.08% | 13.69% | 6.38% | 4.33% | | Multi-Omics Big Data Services and Synthesis Business | 303,784,226.03 | 189,495,961.42 | 37.62% | -7.49% | -19.20% | 9.04% | | Precision Medicine Testing Integrated Solutions | 664,210,388.09 | 252,242,193.60 | 62.02% | -17.00% | -22.56% | 2.72% | [Risks Faced by the Company and Countermeasures](index=66&type=section&id=X.%20Risks%20Faced%20by%20the%20Company%20and%20Countermeasures) The company faces risks from market competition, policy changes, overseas operations (especially US legislation), exchange rate fluctuations, and supply chain issues, with countermeasures including innovation and compliance - Intensified market competition: Rapid industry growth and new entrants lead to declining prices, potentially impacting gross margins and profitability[152](index=152&type=chunk) - Industry policy change risks: Adjustments in domestic and international industry policies and regulations (e.g., high-throughput sequencing, human genetic resource management, data security) may adversely affect operations[153](index=153&type=chunk) - Overseas business risks: The US listing of some subsidiaries on the "Entity List" and the advancement of the "Biosecurity Act" may restrict the company's US business development and supply chain, potentially impacting operations and profitability[156](index=156&type=chunk)[157](index=157&type=chunk) - Supply chain risks: Reliance on overseas suppliers for some raw materials and related-party procurement may lead to unstable supply or increased transaction costs, adversely affecting business operations[160](index=160&type=chunk) [Corporate Governance](index=70&type=section&id=Item%204.%20Corporate%20Governance) This section details the company's corporate governance structure, including information on its equity incentive plans and employee stock ownership programs [Equity Incentive and Employee Stock Ownership Plans](index=71&type=section&id=IV.%20Implementation%20of%20Company%20Equity%20Incentive%20Plans%2C%20Employee%20Stock%20Ownership%20Plans%2C%20or%20Other%20Employee%20Incentive%20Measures) The company is implementing its 2022 restricted stock incentive plan and second employee stock ownership plan, with the first vesting period completed and the first lock-up period expired - The 2022 restricted stock incentive plan granted a total of **8.20 million shares** to management and core business personnel, with 2023-2025 as assessment years and non-COVID-related operating revenue growth as the key performance indicator[170](index=170&type=chunk)[173](index=173&type=chunk) - During the reporting period, the first vesting period of the 2022 incentive plan's initial grant was completed, with **1.91 million shares** vested by 446 individuals at a price of **27.83 RMB/share**[181](index=181&type=chunk) - The second employee stock ownership plan involves 42 holders, owning **4.00 million shares**, representing **0.96%** of the company's total share capital, with **21.70 million RMB** in amortization expenses during the reporting period[182](index=182&type=chunk)[187](index=187&type=chunk) [Environmental and Social Responsibility](index=77&type=section&id=Item%205.%20Environmental%20and%20Social%20Responsibility) This section outlines the company's commitment to environmental protection and social welfare, detailing its initiatives in public health and community support [Social Responsibility Performance](index=77&type=section&id=II.%20Social%20Responsibility%20Performance) The company actively fulfills social responsibilities through public welfare projects like birth defect and oncology prevention, conducting numerous free clinics and supporting thalassemia and ALS patients - The company conducted nearly a hundred free clinic events, providing free genetic testing and counseling services to patients with hereditary diseases and their families, benefiting a cumulative **20,000 person-times**[192](index=192&type=chunk) - Through the "Hua Foundation" and "Tianxia Wupin Foundation," **21,089** severe thalassemia public welfare samples were completed, helping **765** children find fully matched donors and assisting nearly **50** children with severe thalassemia in completing hematopoietic stem cell transplants[192](index=192&type=chunk)[193](index=193&type=chunk) [Significant Matters](index=79&type=section&id=Item%206.%20Significant%20Matters) This section covers critical events and disclosures, including ongoing litigation, significant related-party transactions, and other material developments affecting the company [Litigation Matters](index=89&type=section&id=VIII.%20Litigation%20Matters) The company disclosed multiple litigation and arbitration cases, including significant equity repurchase disputes totaling **339 million RMB** still under review, and a contract dispute with a supplier for **98.83 million RMB** - The company is involved in four equity repurchase disputes with investment institutions, totaling approximately **726 million RMB**, with one case settled and three ongoing, amounting to **339 million RMB** in unresolved claims[208](index=208&type=chunk)[211](index=211&type=chunk) - The company is involved in a contract dispute with a supplier, where the claim amount was revised from **649 million RMB** to **98.83 million RMB**, with the first-instance trial pending[209](index=209&type=chunk)[210](index=210&type=chunk) [Significant Related Party Transactions](index=94&type=section&id=XI.%20Significant%20Related%20Party%20Transactions) The primary related-party transaction involved purchasing equipment, materials, and services from MGI and its subsidiaries, totaling **340.06 million RMB**, within the approved annual limit Significant Related Party Transactions Related to Ordinary Operations | Related Party | Content of Related Party Transaction | Amount of Related Party Transaction (Million RMB) | Percentage of Similar Transactions | Approved Transaction Limit (Million RMB) | | :--- | :--- | :--- | :--- | :--- | | MGI and its Subsidiaries | Equipment, Materials, After-sales Services, etc. | 340.06 | 34.97% | 940.09 | [Share Changes and Shareholder Information](index=101&type=section&id=Item%207.%20Share%20Changes%20and%20Shareholder%20Information) This section details changes in the company's share capital and provides an overview of its shareholder structure, including major shareholders and their holdings [Share Change Status](index=101&type=section&id=I.%20Share%20Change%20Status) During the reporting period, the company's total share capital increased by **1.91 million shares** to **415.82 million shares** due to the vesting of the 2022 restricted stock incentive plan - During the reporting period, the company's total share capital increased by **1.91 million shares** due to equity incentive vesting, reaching **415.82 million shares** at period-end[231](index=231&type=chunk)[232](index=232&type=chunk)[233](index=233&type=chunk) [Number of Shareholders and Shareholding Status](index=104&type=section&id=III.%20Number%20of%20Shareholders%20and%20Shareholding%20Status) As of the reporting period, the company had **66,523** common shareholders, with the controlling shareholder and its concerted parties holding **37.34%** of shares, and institutional investors prominent among the top ten Top Ten Shareholders' Shareholding Status | Shareholder Name | Shareholder Nature | Shareholding Percentage | Number of Shares Held at Period-End (shares) | | :--- | :--- | :--- | :--- | | Shenzhen BGI Genomics Co., Ltd. | Domestic Non-State-Owned Legal Person | 35.78% | 148,773,893 | | Shenzhen Shenghua Investment Enterprise (Limited Partnership) | Domestic Non-State-Owned Legal Person | 8.29% | 34,470,455 | | Bank of Communications - Wanjia Industry Selection Mixed Fund (LOF) | Other | 2.24% | 9,333,338 | | Bank of China - Huabao CSI Healthcare ETF | Other | 1.91% | 7,961,273 | | Industrial and Commercial Bank of China - E Fund ChiNext ETF | Other | 1.14% | 4,758,199 | | BGI Genomics Co., Ltd. - Second Employee Stock Ownership Plan | Other | 0.96% | 4,000,141 | | Shenzhen BGI SanShengYuan Technology Co., Ltd. | Domestic Non-State-Owned Legal Person | 0.95% | 3,935,824 | | Agricultural Bank of China - CSI 500 ETF | Other | 0.73% | 3,049,600 | | He Qianxing | Domestic Natural Person | 0.68% | 2,820,936 | | HKSCC Nominees Limited | Overseas Legal Person | 0.62% | 2,595,430 | - Controlling shareholder BGI Holdings and its concerted parties, BGI SanShengYuan and Mr. Wang Jian, collectively hold **155.25 million shares**, representing **37.34%** of total share capital, with **92.56 million shares** pledged, accounting for **59.62%** of their combined holdings and **22.26%** of the company's total share capital[226](index=226&type=chunk) [Financial Report](index=112&type=section&id=Item%2010.%20Financial%20Report) This section presents the company's unaudited consolidated and parent company financial statements, including balance sheets, income statements, cash flow statements, and statements of changes in equity [Financial Statements](index=112&type=section&id=II.%20Financial%20Statements) This chapter provides unaudited consolidated and parent company financial statements, showing total assets of **13.38 billion RMB** (down 1.70%) and net assets attributable to shareholders of **10.04 billion RMB** (up 1.82%) Key Items from Consolidated Balance Sheet | Item | Period-End Balance (RMB) | Period-Beginning Balance (RMB) | | :--- | :--- | :--- | | Cash and Cash Equivalents | 4,467,509,222.88 | 4,732,376,385.95 | | Accounts Receivable | 1,734,733,017.31 | 1,443,946,645.90 | | Inventories | 604,186,007.28 | 602,182,084.31 | | Fixed Assets | 2,633,901,519.06 | 2,652,013,243.12 | | Total Assets | 13,381,067,622.14 | 13,613,007,886.01 | | Total Liabilities | 3,195,998,382.48 | 3,608,987,599.21 | | Total Equity Attributable to Parent Company Owners | 10,039,089,191.14 | 9,859,237,734.19 | Key Items from Consolidated Income Statement | Item | H1 2024 (RMB) | H1 2023 (RMB) | | :--- | :--- | :--- | | Total Operating Revenue | 1,871,450,587.02 | 2,071,830,715.34 | | Operating Cost | 987,547,295.68 | 1,120,165,357.30 | | Research and Development Expenses | 250,247,428.23 | 264,583,009.67 | | Total Profit | 25,334,359.06 | 62,670,835.28 | | Net Profit | 20,153,227.36 | 49,964,211.86 | | Net Profit Attributable to Parent Company Shareholders | 18,199,776.02 | 49,788,771.48 |

本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、深圳华大基因股份有限公司（以下简称公司）第四届监事会第二次会议 于2024年8月12日通过电子邮件形式送达至全体监事，通知中包括会议的相关材 料，同时列明了会议的召开时间、内容和方式。 2、本次监事会于2024年8月22日在公司会议室召开，以现场与通讯相结合的 方式进行表决（其中监事刘斯奇、胡宇洁以通讯方式参加会议）。 3、本次监事会应参加表决监事3名，实际参加表决监事3名。 证券代码：300676 证券简称：华大基因 公告编号：2024-060 深圳华大基因股份有限公司 第四届监事会第二次会议决议公告 经审核，与会监事认为：该专项报告真实、准确、完整地反映了公司2024年 上半年的募集资金存放与使用情况。公司2024年半年度募集资金的存放与使用情 况符合中国证监会、深圳证券交易所以及公司关于募集资金管理的相关规定，不 存在违规管理与使用募集资金的情形，不存在变相改变募集资金用途和损害中小 股东利益的情形。 《2024年半年度报告》《2024年半年度报告摘要》《2024年半年度非经营性 ...

证券代码：300676 证券简称：华大基因 公告编号：2024-058 深圳华大基因股份有限公司 关于控股股东及其一致行动人部分股份解除质押及再质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 深圳华大基因股份有限公司（以下简称公司或上市公司）近日收到公司控股股东 深圳华大基因科技有限公司（以下简称华大控股）、华大控股的控股子公司暨一致行 动人深圳华大三生园科技有限公司（以下简称华大三生园）的通知，获悉华大三生园 将其质押的公司股份办理了解除质押，华大控股将其持有的部分公司股份办理了解 除质押及再质押，相应的解除质押及再质押登记手续已通过中国证券登记结算有限 责任公司深圳分公司办理完毕。现将具体内容公告如下： 一、控股股东及其一致行动人部分股份解除质押及再质押的基本情况 | 股东名称 | 是否为控股 股东或第一 | 本次解除质押 股份数量 | 占其所持 | 占公司 总股本 | 质押起始 | 质押解除 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 大股东及其 | （股） | ...

证券代码：300676 证券简称：华大基因 公告编号：2024-057 深圳华大基因股份有限公司 2023 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、深圳华大基因股份有限公司（以下简称公司或本公司）2023 年度利润分配 方案披露至实施期间，因 2022 年限制性股票激励计划首次授予部分第一个归属期 的归属股份上市流通导致参与权益分派的总股本增加，公司 2023 年年度权益分 派实施分配方案为：以现有总股本 415,821,575 股为基数，每 10 股派发现金股利 人民币 1.00 元（含税），派发现金股利总额为 41,582,157.50 元（以下元均指人民币 元）。2023 年度公司不实施以资本公积金转增股本，不送红股。 2、本次权益分派实施后计算除权除息价格时，按照每股分配比例不变的原则， 以公司总股本 415,821,575 股折算后的每 10 股现金分红红利=现金分红总额÷总股 本×10=41,582,157.50 元÷415,821,575 股×10=1.000000 元。除权除息参考价=权益 分派股 ...

证券代码：300676 证券简称：华大基因 公告编号：2024-055 深圳华大基因股份有限公司 关于独立董事取得独立董事培训证明的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳华大基因股份有限公司（以下简称公司）于 2024 年 6 月 18 日召开 2024 年第二次临时股东大会，审议通过了《关于公司董事会换届选举第四届董事会独 立董事的议案》，选举侯志波先生为第四届董事会独立董事，任期自 2024 年第二 次临时股东大会选举通过之日起三年。 截至 2024 年第二次临时股东大会通知发出之日，侯志波先生尚未取得深圳 证券交易所认可的独立董事培训证明，根据《上市公司独立董事管理办法》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法 律法规的有关规定，为更好地履行独立董事职责，侯志波先生已书面承诺参加深 圳证券交易所组织的最近一次独立董事培训，并取得深圳证券交易所认可的独立 董事资格证书。 2024年6月20日 近日，公司董事会收到独立董事侯志波先生的通知，其已按照相关规定参加 了深圳证券交易所举办的上市公司独立董事 ...

证券代码：300676 证券简称：华大基因 公告编号：2024-054 深圳华大基因股份有限公司 关于完成董事会、监事会换届选举及聘任高级管理人员、内审 内控部负责人、证券事务代表的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳华大基因股份有限公司（以下简称公司）第三届董事会、监事会、高级 管理人员任期将于 2024 年 6 月届满。公司于 2024 年 5 月 31 日召开职工代表大 会，于 2024 年 6 月 18 日召开 2024 年第二次临时股东大会、第四届董事会第一 次会议和第四届监事会第一次会议，完成了董事会、监事会的换届选举和高级管 理人员的换届聘任等事项。现将相关情况公告如下： 一、公司第四届董事会、监事会和高级管理人员的选举和聘任情况 公司于 2024 年 5 月 31 日召开的第三届董事会第二十六次会议、第三届监事 会第二十六次会议，以及 2024 年 6 月 18 日召开的 2024 年第二次临时股东大会 审议通过了《关于公司董事会换届选举第四届董事会非独立董事的议案》《关于 公司董事会换届选举第四届董事会独立董事的议案》《 ...

证券代码：300676 证券简称：华大基因 公告编号：2024-051 深圳华大基因股份有限公司 2024 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 ② 通过深圳证券交易所互联网投票系统进行网络投票的具体时间为：2024 年6月18日9:15至2024年6月18日15:00期间的任意时间。 2、会议召开地点：广东省深圳市盐田区梅沙街道云华路9号华大时空中心 C 区国际会议中心419会议室 3、会议召开方式：本次股东大会采取现场表决与网络投票相结合的方式 重要提示： 1、本次股东大会召开期间不存在增加、否决或变更议案情形； 2、本次股东大会未涉及变更前次股东大会决议的情形。 一、会议召开情况 1、会议召开的日期、时间： （1）现场会议召开时间：2024年6月18日（星期二）14:00 （2）网络投票时间： ① 通过深圳证券交易所交易系统进行网络投票的具体时间为：2024年6月18 日9:15—9:25，9:30—11:30和13:00—15:00； 4、会议召集人：深圳华大基因股份有限公司（以下简称公司）董事会 5、会议主持人 ...

3、本次监事会应参加表决监事3名，实际参加表决监事3名。 4、本次监事会由全体监事一致同意推举监事张金锋先生召集和主持。公司 董事会秘书和证券事务代表列席了本次监事会。 证券代码：300676 证券简称：华大基因 公告编号：2024-053 深圳华大基因股份有限公司 第四届监事会第一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、深圳华大基因股份有限公司（以下简称华大基因或公司）于2024年6月18 日召开2024年第二次临时股东大会选举产生第四届监事会非职工代表监事后，为 保证监事会工作的有效衔接，公司第四届监事会第一次会议通知于2024年6月18 日当天以现场口头通知、电话等形式送达至全体监事，通知中包括会议的相关材 料，同时列明了会议的召开时间、内容和方式。 2、本次监事会于2024年6月18日在公司会议室召开，以现场与通讯相结合的 方式进行表决（其中监事刘斯奇以通讯方式参加会议）。 特此公告。 深圳华大基因股份有限公司监事会 表决结果：3票赞成，0票反对，0票弃权。 三、备查文件 《第四届监事会第一次会议决议 ...